STOCK TITAN

Axalta to Hold Special Meeting of Stockholders on Proposed Merger with AkzoNobel on August 5, 2026

(Moderate)
(Neutral)

Axalta (NYSE: AXTA) announced that the SEC has declared effective AkzoNobel’s Form F-4 registration statement for their proposed all-share merger of equals. Axalta filed a definitive proxy and set a special stockholder meeting for 9 a.m. EDT on August 5, 2026.

Completion of the Merger depends on shareholder and regulatory approvals and other customary conditions, and is expected around late 2026 or early 2027. Proxy materials are available on Axalta’s investor relations website.

Loading...
Loading translation...

Positive

  • SEC effectiveness of AkzoNobel Form F-4 advances proposed merger process
  • Special meeting of Axalta stockholders set for August 5, 2026
  • Estimated merger completion window of late 2026 or early 2027 provides timing visibility

Negative

  • Merger remains subject to approvals from both Axalta and AkzoNobel shareholders
  • Transaction also requires regulatory approvals and other customary closing conditions
  • Closing timeline disclosed only as a broad late-2026 to early-2027 window

News Market Reaction – AXTA

+3.03%
+3.03% Session close to close

In the Jun 24 session, AXTA gained 3.03%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement advances the AkzoNobel merger by setting the August 5 special meeting and reiterat...
Analysis

This announcement advances the AkzoNobel merger by setting the August 5 special meeting and reiterating an end-2026 to early-2027 closing goal. Key risks remain regulatory approvals and shareholder votes; investors will watch for further filing updates.

Key Figures

Special meeting time: 9 a.m. EDT Special meeting date: August 5, 2026 Expected completion window: End of 2026 or beginning of 2027
3 metrics
Special meeting time 9 a.m. EDT Axalta special meeting of stockholders on merger
Special meeting date August 5, 2026 Scheduled vote on proposed merger with AkzoNobel
Expected completion window End of 2026 or beginning of 2027 Targeted closing period for Axalta–AkzoNobel merger

Previous Acquisition Reports

2 past events · Latest: Nov 18 (Positive)
Same Type Pattern 2 events
Date Event Sentiment 24h Move Catalyst
Nov 18 Merger announcement Positive -0.6% Announced all-stock merger of equals with AkzoNobel and synergy targets.
Jul 02 Bolt-on acquisition Positive +0.6% Completed acquisition of The CoverFlexx Group to expand refinish offerings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past acquisition and merger news for Axalta has produced small, mixed price reactions.

Key Terms

form f-4, merger of equals, proxy statement, regulatory approvals
4 terms
form f-4 regulatory
"the registration statement on Form F-4 filed by Akzo Nobel N.V."
Form F-4 is an official filing with the U.S. Securities and Exchange Commission used by non-U.S. companies when they offer securities in connection with mergers, acquisitions, exchange offers or similar transactions. It acts like a detailed product label or instruction manual that explains the deal, the securities being offered, financials, risks and voting requirements, and it matters to investors because it provides the essential facts needed to evaluate how the transaction could affect ownership, value and future returns.
merger of equals financial
"in connection with the proposed all-share merger of equals between Axalta and AkzoNobel"
A merger of equals is when two companies of similar size and value combine into a single business with shared ownership and leadership, rather than one company buying the other. Investors care because it reshuffles who owns and controls the combined company, aims to cut duplicate costs and strengthen market position, but also brings integration risks that can affect future profits and each company’s stock value.
proxy statement regulatory
"Axalta has filed a definitive proxy statement and has scheduled a Special Meeting"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
View in glossary
regulatory approvals regulatory
"subject to approval by Axalta and AkzoNobel shareholders, receipt of required regulatory approvals"
Regulatory approvals are official permissions from government agencies that a company needs before launching a new product, service, or business activity. They matter because without this approval, the company might not be allowed to operate legally or sell its products, similar to how a driver needs a license to legally drive a car.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

PHILADELPHIA, June 24, 2026 (GLOBE NEWSWIRE) -- Axalta Coating Systems Ltd. (NYSE: AXTA) (“Axalta”) announces that yesterday the U.S. Securities and Exchange Commission declared effective the registration statement on Form F-4 filed by Akzo Nobel N.V. (“AkzoNobel”) in connection with the proposed all-share merger of equals between Axalta and AkzoNobel (the “Merger”).

Axalta has filed a definitive proxy statement and has scheduled a Special Meeting of Stockholders to be held at 9 a.m. EDT on Wednesday, August 5, 2026. The definitive proxy statement contains further details regarding the Merger and the matters to be considered by Axalta stockholders.

Completion of the Merger remains subject to approval by Axalta and AkzoNobel shareholders, receipt of required regulatory approvals and other customary closing conditions. Subject to satisfaction of those conditions, completion of the Merger is expected to occur at the end of 2026 or beginning of 2027.

The definitive proxy statement and other relevant materials are available on Axalta’s investor relations website.

About Axalta
Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful and sustainable coatings solutions. From light vehicles, commercial vehicles and refinish applications to electric motors, building facades and other industrial applications, our coatings are designed to prevent corrosion, increase productivity and enhance durability. With more than 150 years of experience in the coatings industry, the global team at Axalta continues to find ways to serve our more than 100,000 customers in over 140 countries better every day with the finest coatings, application systems and technology. For more information visit axalta.com and follow us on LinkedIn.

General restrictions
This communication is not for release, publication, or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication, or distribution would be unlawful.

This communication is not a prospectus and the information in this communication is not intended to be complete. This communication is for informational purposes only and is not intended to be and shall not constitute a solicitation of any vote or approval, or an offer to buy or sell, or the solicitation of an offer to buy or sell, any securities, or an invitation or recommendation to subscribe for, acquire or buy securities of AkzoNobel or Axalta or any other financial products or securities, in any place or jurisdiction, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended (the “Securities Act”).

Any decision to purchase, subscribe for, otherwise acquire, sell or otherwise dispose of any securities must be made only on the basis of the information contained in and incorporated by reference into the prospectus with respect to the shares to be allotted by AkzoNobel in the proposed transaction, which was published on June 24, 2026.

The distribution of this communication may, in some countries, be restricted by law or regulation. Accordingly, persons who come into possession of this document should inform themselves of and observe these restrictions. To the fullest extent permitted by applicable law, AkzoNobel and Axalta disclaim any responsibility or liability for the violation of any such restrictions by any person. Neither AkzoNobel, nor Axalta, nor any of their advisors assume any responsibility for any violation by any person of any of these restrictions. Shareholders of AkzoNobel and Axalta, respectively, with any doubt as to their position should consult an appropriate professional advisor without delay.

This communication is addressed to and directed only at, persons who are outside the United Kingdom or, in the United Kingdom, at persons who are: (i) persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (ii) persons falling within Article 49(2)(a) to (d) of the Order, or (iii) persons to whom it may otherwise lawfully be communicated pursuant to the Order (all such persons together being referred to as, “Relevant Persons”). This communication is directed only at Relevant Persons. Other persons should not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with such persons. Solicitations resulting from this communication will only be responded to if the person concerned is a Relevant Person.

Additional Information and Where to Find It
In connection with the proposed transaction between AkzoNobel and Axalta, AkzoNobel filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4 on May 27, 2026, as amended on June 18, 2026, which included a proxy statement of Axalta that also constitutes a prospectus with respect to the shares to be offered by AkzoNobel in the proposed transaction. The registration statement was declared effective by the SEC on June 23, 2026. In connection with the proposed transaction, on June 24, 2026, Axalta filed with the SEC a definitive proxy statement and, on or about June 24, 2026, Axalta commenced mailing the definitive proxy statement to its holders of record as of June 11, 2026. Each of AkzoNobel and Axalta will also file other relevant documents in connection with the proposed transaction. This communication is not a substitute for any registration statement, proxy statement/prospectus or other documents AkzoNobel and/or Axalta may file with the SEC or any other competent regulator in connection with the proposed transaction. This communication does not contain all the information that should be considered concerning the proposed transaction and is not intended to form the basis of any investment decision or any other decision in respect of the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISIONS, INVESTORS, STOCKHOLDERS AND SHAREHOLDERS OF AKZONOBEL AND AXALTA ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT/PROSPECTUS, AS APPLICABLE, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT AKZONOBEL, AXALTA, THE PROPOSED TRANSACTION AND RELATED MATTERS. The registration statement and proxy statement/prospectus and other relevant documents filed by AkzoNobel and Axalta with the SEC are available free of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed with the SEC from Axalta’s investor relations webpage at https://ir.axalta.com/sec-filings/all-sec-filings or from AkzoNobel’s investor relations webpage at https://www.akzonobel.com/en/investors/all-sec-filings.

The contents of this communication should not be construed as financial, legal, business, investment, tax or other professional advice. Each recipient should consult with its own professional advisors for any such matter and advice.

Participants in the Solicitation
This communication is not a solicitation of proxies in connection with the proposed transaction. However, under SEC rules, AkzoNobel, Axalta and certain of their respective directors and executive officers and other members of their respective management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction, including a description of their direct or indirect interests in the proposed transaction, by security holdings or otherwise, is set forth in the definitive proxy statement/prospectus relating to the proposed transaction, which was filed with the SEC on June 24, 2026. Information about AkzoNobel’s supervisory board members and members of the board of management is set forth in AkzoNobel’s latest annual report, as filed with the AFM, the Dutch trade register and on its website at https://www.akzonobel.com/en/investors/results-center, and as updated from time to time via filings made by AkzoNobel with the AFM. Additional information regarding the interests of persons who may, under the rules of the SEC, be deemed participants in the solicitation of Axalta security holders in connection with the proposed transaction, which may, in some cases, be different than those of Axalta’s shareholders generally, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus and other relevant materials when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Cautionary Statement Concerning Forward-Looking Statements
This communication contains forward-looking statements as that term is defined in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, regarding, among other things, statements about management’s expectations of AkzoNobel’s and Axalta’s future operating and financial performance, product development, market position, and business strategy. Such forward-looking statements can sometimes be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “potential,” “seeks,” “aims,” “projects,” “predicts,” “is optimistic,” “intends,” “plans,” “estimates,” “targets,” “anticipates,” “continues” or other comparable terms or negatives of these terms, but not all forward-looking statements include such identifying words. You are cautioned not to rely on these forward-looking statements. Forward-looking statements are based upon current plans, estimates and expectations that are subject to risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. We can give no assurance that such plans, estimates or expectations will be achieved and therefore, actual results may differ materially from any plans, estimates or expectations in such forward-looking statements. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include: a condition to the closing of the proposed transaction may not be satisfied; the occurrence of any event that can give rise to termination of the proposed transaction; a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; AkzoNobel and Axalta are unable to achieve the synergies and value creation contemplated by the proposed transaction; AkzoNobel and Axalta are unable to promptly and effectively integrate their businesses; management’s time and attention is diverted on transaction related issues; the possibility that competing offers or acquisition proposals may be made; disruption from the proposed transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of AkzoNobel or Axalta decline following the proposed transaction; legal proceedings are instituted against AkzoNobel or Axalta, including resulting expense or delay; AkzoNobel or Axalta is unable to retain or hire key personnel; the communication or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of AkzoNobel or Axalta or on AkzoNobel’s or Axalta’s operating results; evolving legal, regulatory and tax regimes; changes in economic, financial, political and regulatory conditions, in the Netherlands, the United States and elsewhere, and other factors that contribute to uncertainty and volatility, natural and man-made disasters, civil unrest, pandemics (e.g., the coronavirus (COVID-19) pandemic), geopolitical uncertainty, and conditions that may result from legislative, regulatory, trade and policy changes associated with the current or subsequent United States or Netherlands administration; the ability of AkzoNobel or Axalta to successfully recover from a disaster or other business continuity problem due to a hurricane, flood, earthquake, terrorist attack, war, pandemic, security breach, cyber-attack, power loss, telecommunications failure or other natural or man-made event, including the ability to function remotely during long-term disruptions; the impact of public health crises, such as pandemics and epidemics and any related company or governmental policies and actions to protect the health and safety of individuals or governmental policies or actions to maintain the functioning of national or global economies and markets, including any quarantine, “shelter in place,” “stay at home,” workforce reduction, social distancing, shut down or similar actions and policies; actions by third parties, including government agencies; the risk that disruptions from the proposed transaction will harm AkzoNobel’s or Axalta’s business, including current plans and operations and/or divert management’s attention from AkzoNobel’s or Axalta’s ongoing business operations; certain restrictions during the pendency of the acquisition that may impact AkzoNobel’s or Axalta’s ability to pursue certain business opportunities or strategic transactions; AkzoNobel’s or Axalta’s ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; the risks and uncertainties discussed in AkzoNobel’s latest annual report as filed with the AFM, the Dutch trade register and on its website at https://www.akzonobel.com/en/investors/results-center; and the risks and uncertainties discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in Axalta’s reports filed with the SEC. These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the proxy statement/prospectus. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. We caution you not to place undue reliance on any of these forward-looking statements as they are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of new markets or market segments in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this communication. Except as required by law, neither AkzoNobel nor Axalta assumes any obligation to update or revise the information contained herein, which speaks only as of the date hereof.

   
Axalta Coating Systems
1050 Constitution Ave.
Philadelphia, PA 19112
axalta.com
Investor Relations Contact
Colleen Lubic
+1 610-999-9407
colleen.lubic@axalta.com
Media Contact
axalta-media-relations@axalta.com



FAQ

What did Axalta (NYSE: AXTA) announce about its special meeting on the AkzoNobel merger?

Axalta announced a special meeting of stockholders on August 5, 2026 at 9 a.m. EDT to consider the proposed merger with AkzoNobel. According to Axalta, the definitive proxy statement with merger details is available on its investor relations website for stockholder review.

When is the Axalta (AXTA) and AkzoNobel merger expected to close?

The Axalta and AkzoNobel merger is expected to be completed at the end of 2026 or beginning of 2027, subject to conditions. According to Axalta, closing depends on shareholder approvals, required regulatory clearances, and other customary closing conditions being satisfied.

What regulatory milestone did the Axalta and AkzoNobel merger achieve in June 2026?

The Axalta and AkzoNobel merger obtained SEC effectiveness of AkzoNobel’s Form F-4 registration statement in June 2026. According to Axalta, this declaration of effectiveness is tied to the proposed all-share merger of equals between the two companies and supports the transaction process.

What conditions must be met before the Axalta (AXTA) and AkzoNobel merger can be completed?

The merger must receive approval from Axalta and AkzoNobel shareholders, along with required regulatory approvals and other customary closing conditions. According to Axalta, completion of the transaction is contingent on these conditions and is targeted for late 2026 or early 2027.

Where can Axalta (AXTA) investors find the definitive proxy materials for the AkzoNobel merger vote?

Axalta investors can access the definitive proxy statement and related materials on the company’s investor relations website. According to Axalta, these documents provide detailed information about the proposed all-share merger of equals and the matters to be considered at the August 5, 2026 special meeting.

What type of transaction is proposed between Axalta (AXTA) and AkzoNobel?

Axalta and AkzoNobel have proposed an all-share merger of equals, subject to shareholder and regulatory approvals. According to Axalta, the transaction structure involves combining the companies through share consideration, with further specifics described in AkzoNobel’s Form F-4 and Axalta’s definitive proxy.